Funding & VC

Luminoah Banks $25 Million Series B to Scale Tube-Feeding Device

Luminoah raised $25 million in Series B funding led by Sandbox Clinical Ventures to expand US distribution of its pocket-sized, FDA-cleared enteral feeding pump and clinician data platform.

By Olivia Hart

5 min read

Luminoah Raises $25 Million Series B To Expand Enteral Feeding Technology
Luminoah Raises $25 Million Series B To Expand Enteral Feeding Technologyfernandozhiminaicela / pixabay

What's News

  • Luminoah raised $25 million in Series B: $20 million new equity plus $5 million converted notes, led by Sandbox Clinical Ventures.
  • Luminoah Flow received FDA clearance in April 2026.
  • The company, founded in 2020 in Charlottesville, Virginia, will expand distribution through home medical equipment suppliers and health systems.
  • Investors include GV, Sands Capital, Blue Venture Fund, and the AGA GI Opportunity Fund.
  • COO Garrett Marin says the financing targets reaching 'thousands of patients' via distribution, manufacturing scale, and clinician software.

Luminoah has closed a $25 million Series B round to scale its FDA-cleared enteral feeding system, with Sandbox Clinical Ventures leading the financing. The round splits into $20 million of new equity and $5 million in previously issued convertible notes that converted as part of the transaction.

The investor roster is unusually broad for a device company of this size. Beyond Sandbox Clinical Ventures, participants include the Blue Venture Fund, GV, Sands Capital, Texas Medical Center Venture Fund, the CU Healthcare Innovation Fund, the American Gastroenterological Association GI Opportunity Fund, and existing backers. Notably, two of those investors are themselves healthcare institutions — a signal that hospitals and physician societies see a commercial stake in the technology, not just a financial one.

What does the money buy?

The company has assigned the capital to three specific tasks. Luminoah will:

  • Expand distribution of its Luminoah Flow system through home medical equipment suppliers and health systems across the United States.
  • Increase production capacity and add manufacturing automation.
  • Continue developing Luminoah Intelligence, its data platform for clinicians.

Garrett Marin, Luminoah's Chief Operating Officer, framed the sequencing plainly. "Early access showed us how Luminoah Flow fits into a patient's daily routine. Reaching thousands of patients takes distribution partners, manufacturing at scale, and software clinicians will actually use. Our Series B financing enables us to focus on these key initiatives," Marin said.

The phrase "thousands of patients" is worth noting as the company's own scale target. It also implies the current user base is smaller — the company has not disclosed how many patients used the system during its early-access phase.

What is Luminoah Flow?

The system received FDA clearance in April 2026. It combines three components: a pocket-sized rechargeable feeding pump, nutrition pouches, and a connected mobile application. The design goal is mobility — patients can receive nutrition while moving through daily routines rather than staying tethered to a larger pump or an equipment pole.

After clearance, Luminoah ran an early-access program with patients served by healthcare institutions in the Pacific Northwest and Southeast. The company did not disclose participant numbers or clinical outcomes from that program, so claims about real-world performance rest on the company's own account rather than published data.

Feeding information uploads to the mobile app. When patients choose to share their data, clinicians can use Luminoah Intelligence to review delivered nutrition and gain visibility into therapy outside clinical settings. The consent model puts data sharing under patient control — a design choice that reduces privacy friction but could also limit how much data clinicians actually see.

Who is behind the company?

Founder and CEO Neal Piper started Luminoah after his son, Noah, required tube feeding during cancer treatment. The company was founded in 2020 and is headquartered in Charlottesville, Virginia. It is now hiring across engineering, operations, and commercial functions as it prepares for broader adoption.

Piper tied the product directly to that experience. "For too long, families who depend on tube feeding have had to organize their lives around the pump. We built Luminoah so the technology could fit around their lives instead. Our family's experience inspired a mission to make tube feeding simpler and give people greater freedom. With patients now using our technology and the support of exceptional investors, we're ready to bring that vision to many more families," Piper said.

The mission framing carries voice. What it does not carry is a revenue figure — Luminoah disclosed no sales, pricing, or reimbursement details, which makes commercial traction impossible to verify from the announcement alone.

How did investors justify the bet?

The backers staked their cases on different parts of the product. Scott Davis, Venture Partner at GV, emphasized the founding story and patient focus. "We're thrilled to partner with Neal and the Luminoah team to transform enteral feeding. Inspired by his family's experience, Neal and the team have developed a patient-first solution that supports more active lives, simplifies feeding, and enables remote tracking for better care. We're excited to support their next chapter," Davis said.

Tom Hawes, Managing Director at the Blue Venture Fund and Sandbox Clinical Ventures, made the most concrete economic argument. "Luminoah is poised to disrupt an outdated and burdensome standard of care in enteral nutrition. By combining compact pump design, a user-friendly interface, and real-time tracking, Luminoah Flow not only improves the patient experience but also directly combats the drivers of poor nutrition plan adherence, which can help prevent hospital readmissions, reduce costs, and free up valuable clinician time," Hawes said.

That readmissions claim is a hypothesis, not a published finding. The company's early-access program has not produced outcome data that Luminoah has made public.

Tom Serena, CEO of the American Gastroenterological Association, cast the deal as filling a long innovation gap. "Enteral nutrition has gone far too long without meaningful innovation. Luminoah is making nutrition therapy more portable, connected, and patient-centered while giving clinicians better information to guide care. That combination of clinical need, patient impact, and thoughtful innovation is exactly what we look for through the AGA GI Opportunity Fund," Serena said.

What happens next?

The capital plan is concrete: distribution agreements, manufacturing automation, and the clinician software platform. The unanswered questions are equally concrete — no disclosed patient counts, no revenue, no published clinical outcomes, and no timeline for when "thousands of patients" becomes a measurable market share in the enteral nutrition sector. The next test is whether home medical equipment suppliers and health systems adopt Luminoah Flow at the scale the Series B investors are now underwriting.

Source: pulse2.com

Share this article:

More from Olivia Hart

Olivia Hart

Show full bio

Staff writer covering people, launches and day-to-day practice in entrepreneurship, startups and venture funding at Business Bearings.

2,205 articles

Related articles

« Previous article